Kalaris Therapeutics Inc (KLRS) Stock Ticker
Market factors today
Unlock the full KLRS picture
About Kalaris Therapeutics Inc
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
KLRS stock facts
| Ticker symbol | KLRS |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $63.7M |
| CEO | Andrew Oxtoby |
| Employees | 20 |
| Headquarters | Berkeley Heights, NJ, US |
| IPO date | 2020-07-30 |
| Website | kalaristx.com |
What you can see for KLRS on Tickr
Live KLRS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the KLRS report.
Rankings
FAQ
What is the ticker symbol for Kalaris Therapeutics Inc?
The ticker symbol for Kalaris Therapeutics Inc is KLRS, listed on the NASDAQ Global Market.
What is KLRS?
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular…